Could a One-Time keyhole surgery replace daily blood thinners for some heart patients?

NCT ID NCT07705282

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial compares a minimally invasive surgery that closes off a small heart pouch (the left atrial appendage) to standard blood-thinning medication in people with atrial fibrillation who have a high risk of bleeding. The goal is to see if the surgery can prevent strokes, major bleeds, and other heart-related events as well as or better than daily pills. Participants are either already on blood thinners or cannot take them due to medical reasons.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
video-assisted thoracoscopic closure of the left atrial appendage using a closure device
What this could lead to
If successful, this procedure could offer a safe alternative to long-term blood thinners for people with atrial fibrillation who are at high risk of bleeding.
What could go wrong
This is a large trial, but surgery carries risks like infection or complications from anesthesia. The procedure may not prove as effective as blood thinners in preventing strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL APPENDAGE CLOSURE FOR ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Skånes universitetssjukhus

    Lund, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.